NYSEAMERICAN:VNRX - VolitionRX Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$3.36 -0.03 (-0.88 %)
(As of 04/22/2019 04:00 PM ET)
Previous Close$3.39
Today's Range$3.28 - $3.40
52-Week Range$1.44 - $3.55
Volume20,913 shs
Average Volume100,541 shs
Market Capitalization$127.06 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
VolitionRX Limited, a life sciences company, engages in the development of blood tests to help diagnose a range of cancers worldwide. The company develops 39 epigenetic Nu.Q blood assays based on its Nucleosomics biomarker discovery platform. VolitionRX Limited is based in Singapore.

Receive VNRX News and Ratings via Email

Sign-up to receive the latest news and ratings for VNRX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Medical Laboratories & Research
Sub-IndustryN/A
SectorMedical
Current SymbolNYSEAMERICAN:VNRX
Previous SymbolNYSEMKT:VNRX
CUSIPN/A
CIKN/A
Phone646 650 1351

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees44
Market Cap$127.06 million
Next Earnings Date5/9/2019 (Estimated)
OptionableNot Optionable

VolitionRX (NYSEAMERICAN:VNRX) Frequently Asked Questions

What is VolitionRX's stock symbol?

VolitionRX trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "VNRX."

How were VolitionRX's earnings last quarter?

VolitionRX Ltd (NYSEAMERICAN:VNRX) released its quarterly earnings data on Wednesday, March, 13th. The medical research company reported ($0.11) EPS for the quarter, topping analysts' consensus estimates of ($0.14) by $0.03. View VolitionRX's Earnings History.

When is VolitionRX's next earnings date?

VolitionRX is scheduled to release their next quarterly earnings announcement on Thursday, May 9th 2019. View Earnings Estimates for VolitionRX.

What price target have analysts set for VNRX?

3 brokers have issued 1-year price targets for VolitionRX's stock. Their predictions range from $5.00 to $6.00. On average, they anticipate VolitionRX's stock price to reach $5.3333 in the next year. This suggests a possible upside of 58.7% from the stock's current price. View Analyst Price Targets for VolitionRX.

What is the consensus analysts' recommendation for VolitionRX?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for VolitionRX in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for VolitionRX.

Has VolitionRX been receiving favorable news coverage?

News headlines about VNRX stock have trended somewhat positive this week, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. VolitionRX earned a news sentiment score of 1.7 on InfoTrie's scale. They also gave media stories about the medical research company a news buzz of 2.0 out of 10, meaning that recent press coverage is very unlikely to have an effect on the company's share price in the near term.

Who are some of VolitionRX's key competitors?

What other stocks do shareholders of VolitionRX own?

Who are VolitionRX's key executives?

VolitionRX's management team includes the folowing people:
  • Dr. Martin Charles Faulkes, Exec. Chairman (Age 75)
  • Mr. Cameron Reynolds, Founder, CEO, Pres & Director (Age 48)
  • Dr. Jacob Vincent Micallef Ph.D., MBA, Chief Scientific Officer (Age 63)
  • Dr. Jason Bradley Terrell, Chief Medical Officer (Age 39)
  • Mr. Rodney Gerard Rootsaert LLB, Corp. Sec. (Age 48)

Who are VolitionRX's major shareholders?

VolitionRX's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Virtu Financial LLC (0.03%). Company insiders that own VolitionRX stock include Cameron John Reynolds, David Cecil Vanston and Guy Archibald Innes. View Institutional Ownership Trends for VolitionRX.

Which institutional investors are buying VolitionRX stock?

VNRX stock was bought by a variety of institutional investors in the last quarter, including Virtu Financial LLC. Company insiders that have bought VolitionRX stock in the last two years include Cameron John Reynolds, David Cecil Vanston and Guy Archibald Innes. View Insider Buying and Selling for VolitionRX.

How do I buy shares of VolitionRX?

Shares of VNRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is VolitionRX's stock price today?

One share of VNRX stock can currently be purchased for approximately $3.36.

How big of a company is VolitionRX?

VolitionRX has a market capitalization of $127.06 million. VolitionRX employs 44 workers across the globe.

What is VolitionRX's official website?

The official website for VolitionRX is http://www.volitionrx.com/.

How can I contact VolitionRX?

The medical research company can be reached via phone at 646 650 1351.


MarketBeat Community Rating for VolitionRX (NYSEAMERICAN VNRX)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  162 (Vote Outperform)
Underperform Votes:  120 (Vote Underperform)
Total Votes:  282
MarketBeat's community ratings are surveys of what our community members think about VolitionRX and other stocks. Vote "Outperform" if you believe VNRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VNRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/22/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel